Department of Pediatrics, University of Trieste, Trieste,Italy.
Institute for maternal and child health IRCCS 'Burlo Garofolo', Trieste,Italy.
Endocr Metab Immune Disord Drug Targets. 2021;21(12):2300-2302. doi: 10.2174/1871530321666210426131423.
We describe the case of an 11-year-old boy affected by chronic granulomatous disease complicated by a Crohn's like colitis needing prolonged treatment with oral corticosteroids.
His therapy for the control of severe oral mucositis was based on topical clobetasol, which did not decrease once the steroids were discontinued. Two years after the oral interruption of the steroids, cushingoid characteristics persisted, the cause of which, after a thorough investigation, was found to be the persistence of the topical clobetasol oral gel.
Several studies investigated the efficacy of topical clobetasol for immuno-related mucositis, but little is known about its pharmacokinetics and side effects. In this report, we have reviewed the literature, defining a maximum putative dose of clobetasol mucosal gel to avoid Cushing syndrome.
我们描述了一例患有慢性肉芽肿病的 11 岁男孩,他患有类似克罗恩病的结肠炎,需要长期口服皮质类固醇治疗。
他的口腔黏膜炎的治疗基于局部应用氯倍他索,但在停用类固醇后并未减轻。在停止使用类固醇两年后,库欣样特征仍然存在,经过彻底调查,发现其原因是局部氯倍他索口腔凝胶的持续存在。
几项研究调查了局部氯倍他索治疗免疫相关性黏膜炎的疗效,但对其药代动力学和副作用知之甚少。在本报告中,我们回顾了文献,确定了氯倍他索口腔凝胶的最大推测剂量,以避免库欣综合征。